Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2024-01-31 Share Issue/Capital Cha…
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Levée de fonds de 250 mille euros
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary subject is the announcement of a capital raise ("Levée de fonds de 250 mille euros") through the issuance of OCEANE-BSA instruments. This directly relates to the company's financing activities and capital structure changes. Based on the provided definitions, the most appropriate category is 'Capital/Financing Update' (CAP). Although it is a press release, its content is highly specific to financing, making CAP more precise than the general 'RNS' fallback.
2024-01-31 French
Pharnext souhaite engager une discussion avec ses actionnaires sur la situation et les perspectives de la Société
AGM Information Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the intention to convene a general meeting of shareholders ("convocation de ses actionnaires en assemblée générale") to discuss the company's situation and outlook. It mentions specific dates for the first and potential second calls for this meeting. This action—announcing a meeting of shareholders to discuss company matters, often preceding a vote or formal decision—is strongly indicative of materials related to an Annual General Meeting (AGM) or a proxy solicitation. Since the core purpose is to call the meeting and discuss the context (including auditor concerns and financial plans), the most fitting category is AGM Information (AGM-R), as it relates directly to the preparation and announcement of the general meeting. It is not the final voting results (DVA) or the proxy statement itself (PSI), but the announcement initiating the process.
2024-01-24 French
Pharnext confirme sa qualification d'Entreprise innovante
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces that Pharnext has confirmed its qualification as an "Entreprise innovante" (Innovative Company) by Bpifrance, which allows access to FCPI investments. This is a specific corporate announcement regarding a regulatory/financial status update, not a full financial report (like 10-K or IR), a transcript (CT), or a dividend notice (DIV). It relates to the company's structure and financing potential. Since it is a specific announcement that doesn't perfectly fit categories like ER, CAP, or LTR, and it is a formal press release, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-standard announcement, or potentially 'Capital/Financing Update' (CAP) due to the mention of FCPI investment eligibility. Given the focus is on the 'qualification' status rather than an immediate financing action, RNS is a safer general classification for non-standard press releases, although CAP is also plausible. I will classify it as RNS as it is a general regulatory/status update announcement.
2024-01-10 French
Information relative au nombre total de droits de vote et d'actions composant le capital social et à la valeur nominale des actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content is the official announcement of the total number of voting rights and shares composing the share capital as of December 31, 2023, referencing French commercial code and AMF regulations (Article L.233-8 II du Code de commerce et article 223-16 du Règlement général de l'Autorité des Marchés Financiers). This specific type of mandatory disclosure regarding the total number of shares and voting rights is typically classified under announcements related to capital structure changes or mandatory regulatory disclosures. Given the options, this directly relates to the composition of the share capital and is a formal notification. While it touches upon capital structure, it is a routine, periodic disclosure of share count rather than a fundraising event (CAP) or a share repurchase (POS). It is a specific regulatory disclosure about the share count. The closest fit among the provided codes for a formal announcement detailing the total number of shares and voting rights is often grouped with capital structure updates or general regulatory filings. Since it explicitly details the total number of shares and voting rights, it falls under the scope of capital structure information. However, it is not a general share issue (SHA) or a buyback (POS), but a mandatory reporting of the current total. In many classification schemes, this type of mandatory disclosure about the share count is often categorized as a general regulatory filing (RNS) or sometimes grouped with capital changes. Given the detailed breakdown of share movements (conversions, BSAE exercises) and the final count, it is a specific capital structure update. Since 'Share Issue/Capital Change' (SHA) covers changes, and this is a report *of* the resulting capital structure, and it's not a general press release about earnings or management, I will evaluate the best fit. It is a formal, periodic disclosure required by regulators concerning the capital base. It is not an earnings release (ER), interim report (IR), or a proxy statement (DEF 14A/PSI). It is most accurately described as a formal regulatory announcement concerning the capital base. If we strictly follow the definitions, 'SHA' is for announcements *regarding* new issues/splits. This is a report *of* the current state resulting from those activities. 'RNS' is the fallback. However, in many contexts, mandatory disclosures about the total number of shares are treated as a specific type of capital announcement. Given the detailed nature of the share count and the reference to regulatory articles, it is a formal capital structure notification. I will classify it as 'SHA' as it is the most relevant category concerning the share count, even if it's a reporting of the current state rather than an announcement of a future change, or as 'RNS' if it's considered a general regulatory filing. Since the document explicitly details the total number of shares and voting rights, which is a core component of capital structure reporting, SHA is a strong candidate. If it were purely a general announcement, RNS would be better. I lean towards SHA due to the specific focus on the capital composition, or RNS as a mandatory regulatory filing. Given the options, and the fact that it's a mandatory disclosure about the capital base, RNS (Regulatory Filings) serves as the most appropriate general category for mandatory, non-financial-statement disclosures that don't fit elsewhere, although it is very close to SHA. I will select RNS as the safest classification for a mandatory regulatory disclosure of share count that isn't an issuance announcement itself.
2024-01-02 French
Regroupement des actions Pharnext et suspension des conversions
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a corporate action: a share consolidation (regroupement des actions) at a ratio of 1 new share for 10,000 old shares, effective in January/February 2024. It also mentions the suspension of the exercise of securities convertible into capital (VMDAC). This type of announcement, detailing a change in the capital structure (share consolidation/split), falls under the 'Share Issue/Capital Change' category. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate action announcement related to capital structure.
2023-12-29 French
Pharnext annonce son intention de préparer des dossiers d'enregistrement et d'autorisation de mise sur le marché de PXT3003, son candidat-médicament dans la maladie de Charcot-Marie-Tooth de type 1A
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the company's intention to prepare registration and marketing authorization dossiers for its drug candidate PXT3003 following an analysis of Phase III clinical trial results. It details the analysis findings, discusses regulatory steps with the FDA and EMA, and includes a quote from management. This structure—a formal announcement of significant business/clinical development updates, often released to the public and investors simultaneously—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement of a major development (clinical results analysis leading to regulatory filing plans), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the context of announcing clinical trial analysis and subsequent regulatory strategy, which is often bundled with earnings or provided as a standalone material update, and since it is not explicitly a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate general category for a significant, non-financial-statement regulatory announcement is RNS. However, because it heavily discusses the results of a clinical trial and the subsequent strategic path, which is often the core content of an Earnings Release (ER) when a company is pre-revenue or focused on R&D milestones, ER is a strong candidate. Given the focus is on the *announcement* of clinical data analysis and regulatory intent, and it is not a full financial report, RNS is the safest fallback for a significant, non-standard announcement. Upon review, the content is a press release detailing clinical trial outcomes and future regulatory strategy, which is a common type of announcement that falls under general regulatory disclosures. I will classify it as RNS (Regulatory Filings) as it is a general regulatory announcement that doesn't fit the more specific financial report codes.
2023-12-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.